. 2015 Mar 18;1(1):e2. doi: 10.2196/publichealth.3310

Table 6.

Topics covered by the HPV vaccination articles before and after Bachmann’s comment.

Topics	Before (n=75)		After (n=125)		χ²	df	P
Topics	Freq.	%	Freq.	%	χ²	df	P
Protection against diseases	67	89.3	97	77.6	4.372^a	1	.04
Vaccine eligibility for females	63	84.0	88	70.4	4.687^a	1	.03
Side effects	44	58.7	74	59.2	0.006	1	.94
Duration	43	57.3	46	36.8	8.002^a	1	.005
Dosing	39	52.0	33	26.4	13.333^a	1	<.001
Vaccine efficacy	37	49.3	55	44.0	0.537	1	.46
Vaccine cost	21	28.0	41	32.8	0.505	1	.48
Politics	19	25.3	54	43.2	6.456^b	1	.01
Vaccine eligibility for males	14	18.7	44	35.2	6.223^b	1	.01

^aCovered more often by the articles published before the Bachmann’s comment (P<.05).

^bCovered more often by the articles published after Bachmann’s comment (P<.05).